Benefit of cilostazol in patients with high risk of bleeding: Subanalysis of cilostazol stroke prevention study 2

Cerebrovascular Diseases

Volumn 37, Issue 4, 2014, Pages 296-303

  Uchiyama, Shinichiro ^a   Shinohara, Yukito ^g   Katayama, Yasuo ^d   Yamaguchi, Takenori ⁱ   Handa, Shunnosuke ^e   Matsuoka, Kempei ^e   Ohashi, Yasuo ^d   Tanahashi, Norio ^h   Yamamoto, Hiroko ^l   Genka, Chokoh ^m   Kitagawa, Yasuhisa ^f   Kusuoka, Hideo ^j   Nishimaru, Katsuya ⁿ   Tsushima, Motoo ^b   Koretsune, Yukihiro ^j   Sawada, Tohru ^k   Hamada, Chikuma ^c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKAI UNIVERSITY TOKYO HOSPITAL   (Japan)

^f TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^g Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^h SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

ⁱ NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

^k Aino Hospital   (Japan)

^l Namiki Hospital   (Japan)

^m Yokohama Asahi Central and General Hospital   (Japan)

ⁿ FUKUOKA UNIVERSITY   (Japan)

more..

Author keywords

Aspirin; Blood pressure; Cilostazol; Hemorrhagic stroke; Lacunar stroke; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

AGE; ARTICLE; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; CHEMICALLY INDUCED; STROKE; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; INCIDENCE; PREVENTION STUDY; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA;

HUMANS; INTRACRANIAL HEMORRHAGES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84899783211     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000360811     Document Type: Article

References (26)

1. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Derry S, Loke YK: Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-1187.
3. Rodríguez LAG, Lin KJ, Hernández-Díaz S, Johansson S: Risk of upper gastrointestinal hemorrhage with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123: 1108-1115.
4. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R: Indications for early aspirin use in acute ischemic stroke. A combined analysis of 4,000 randomized patients from the Chinese acute stroke trial and the international stroke trial. Stroke 2000; 31: 1240-1249.
5. AntithromboticTrialists' (ATT) Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
6. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157.
7. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y; CSPS group: Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the Cilostazol Stroke Prevention Study. Cerebrovasc Dis 2008; 26: 63-70.
8. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C; CASISP cooperation investigators: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
9. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU: Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482-490.
10. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-968.
11. Kamal AK, Naqvi I, Husain MR, Khealani BA: Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011; 19:CD008076.
12. Mizuno K, Nakaya N, Teramoto T, Yokoyama S, Ohashi Y, Ueki A, Takahashi S, Kubota Y, Nakamura H: Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia. J Atheroscler Thromb 2012; 19: 176-185.
13. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Ibayashi S, Iida M: Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry 2005; 76: 368-372.
14. England TJ, Bath PM, Sare GM, Geeganage C, Moulin T, O'Neill D, Woimant F, Christensen H, De Deyn P, Leys D, Ringelstein EB; TAIST Investigators: Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke 2010; 41: 2834-2839.
15. Lavallée PC, Labreuche J, Faille D, Huisse MG, Nicaise-Roland P, Dehoux M, Gongora-Rivera F, Jaramillo A, Brenner D, Deplanque D, Klein IF, Touboul PJ, Vicaut E, Ajzenberg N; Lacunar-BICHAT Investigators: Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis 2013; 36: 131-138.
16. Scherbakov N, Sandek A, Martens-Lobenhoffer J, Kung T, Turhan G, Liman T, Ebinger M, von Haehling S, Bode-Böger SM, Endres M, Doehner W: Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cerebrovasc Dis 2012; 33: 37-46.
17. Diener HC, Weber R: Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke. Stroke 2013; 44: 861-863.
18. The SPS3 Investigators: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817-825.
19. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K; Bleeding with Antithrombotic Therapy (BAT) Study Group: Blood pressure levels and bleeding events during antithrombotic therapy. The Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010; 41: 1440-1444.
20. SPS3 Study Group: Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382: 507-515.
21. Ikeda Y, Sudo T, Kimura Y: Cilostazol; in Michelson AD (ed): Platelets, ed 2. Amsterdam, Elsevier, 2006, pp 1181-1191.
22. Torii H, Kubota H, Ishihara H, Suzuki M: Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res 2007; 55: 104-110.
23. Hashimoto A, Miyakoda G, Hirose Y, Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A-and phosphatidylinositol 3-kinase/Aktdependent mechanism. Atherosclerosis 2006; 189: 350-357.
24. Ishiguro M, Mishiro K, Fujiwara Y, Chen H, Izuta H, Tsuruma K, Shimazawa M, Yoshimura S, Satoh M, Iwama T, Hara H: Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010; 5:e15178.
25. Fujita Y, Lin JX, Takahashi R, Tomimoto H: Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in strokeprone spontaneously hypertensive rats. Brain Res 2008; 1203: 170-176.
26. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A: Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006; 62: 765-772.